by Ryu Hyunseok
Published 21 Oct.2024 14:15(KST)
DeepCure announced on the 21st that the research team led by Professors Park Hyukjin and Hwang Euichang from Chonnam National University presented the laparoscopic renal denervation (RDN) medical device ‘HyperQure’ at the 68th Autumn Scientific Meeting of the Korean Society of Cardiology (KSC 2024). HyperQure is a medical device that treats resistant hypertension by blocking the sympathetic nerves around the renal artery using a laparoscopic method.
KSC 2024 is an international academic conference hosted by the Korean Society of Cardiology and the Korea Heart Research Foundation. It is a gathering where medical professionals and experts in the field of cardiology and cardiovascular diseases share information on the latest medical trends, surgical techniques, and case studies. This year, it was held from the 18th to the 20th of this month at the Grand Walkerhill in Gwangjin-gu, Seoul.
At this conference, the research team of Professors Park Hyukjin and Hwang Euichang presented “Extravascular renal denervation in a patient with resistant hypertension: Experience from first in human trial in Korea.”
The research team performed the procedure on a patient whose systolic blood pressure exceeded 200 mmHg despite taking seven antihypertensive medications using HyperQure. They revealed the patient’s recovery process without side effects and the six-month long-term follow-up results showing blood pressure returning to normal even after discontinuing all antihypertensive drugs. This demonstrated the remarkable efficacy and safety of laparoscopic RDN, which is on a different level from the conventional catheter-based RDN, attracting significant attention from the academic community.
A company representative stated, “The laparoscopic RDN clinical trial presented at this conference is the world’s first extravascular RDN clinical surgery,” adding, “We will strive to successfully commercialize the laparoscopic RDN medical device as soon as possible to provide a new solution for patients suffering from resistant hypertension.”
Meanwhile, DeepCure has been conducting domestic clinical trials of HyperQure on hypertensive patients since January. Surgery has been completed on 6 out of 10 clinical patients, and patient recruitment is planned to be completed within this year. In June of this year, HyperQure received approval for its clinical trial plan (IDE) from the U.S. Food and Drug Administration (FDA), and global clinical trials are scheduled to officially begin in November.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.